REV-ERB agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-19. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
==== Local government finance ==== In 1979 the Conservatives were strongly represented in local government, as a result of the unpopularity of the outgoing Labour government. Four of the five council associations were Conservative-controlled. Heseltine was able to persuade them to rein in their spending by 1% each year. Whereas previously overspending councils had received extra rate support grants from Whitehall, after six months Heseltine announced a list of fourteen overspending councils who were to have their grant cut, most of them inner London councils and only one of them, Hammersmith & Fulham, Conservative controlled. The move appeared blatantly political as many of the other 114 overspenders were Conservative councils. Council leaders who came to appeal to Heseltine were often humiliated by being interrogated about their budget, to demonstrate their lack of detailed knowledge, before the council treasurer was allowed to speak. From 1980 to 1981 relations with local government became increasingly confrontational, as Labour made large gains in local elections, with a new generation of council leaders such as Ken Livingstone in London and David Blunkett in Sheffield seeking to generate employment through their councils. Council spending now began to rise again, largely as a result of increases by the GLC, Merseyside and West Midlands councils; whereas Labour votes tended to be poorer and eligible for rate rebates, the burden of higher spending tended to fall on businesses and middle class homeowners.
β-Amanitin (beta-Amanitin) is a cyclic peptide comprising eight amino acids. It is part of a group of toxins called amatoxins, which can be found in several mushrooms belonging to the genus Amanita. Some examples are the death cap (Amanita phalloides) and members of the destroying angel complex, which includes A. virosa and A. bisporigera. Due to the presence of α-Amanitin, β-Amanitin, γ-Amanitin and epsilon-Amanitin these mushrooms are highly lethal to human beings.
These positive feedbacks on the aging process are counteracted by protective mechanisms: Decreased mTOR activity (among other factors) upregulates removal of dysfunctional cellular components via autophagy. mTOR is a key initiator of the senescence-associated secretory phenotype (SASP). Interleukin 1 alpha (IL1A) is found on the surface of senescent cells where it contributes to the production of SASP factors due to a positive feedback loop with NF-κB. Translation of mRNA for IL1A is highly dependent upon mTOR activity. mTOR activity increases levels of IL1A, mediated by MAPKAPK2. mTOR inhibition of ZFP36L1 prevents this protein from degrading transcripts of numerous components of SASP factors.
=== Ferroptosis === Ferroptosis is a form of regulated cell death characterized by the iron-dependent accumulation of lipid hydroperoxides to lethal levels. ALOX5-mediated ferroptosis acts as a cell death pathway upon oxidative stress in HD. Inhibitors of ferroptosis are protective in models of degenerative brain disorders, including Parkinson's, Huntington's, and Alzheimer's diseases.
Sources: en.wikipedia.org
14 April – Trixie Gardner, Baroness Gardner of Parkes, 96, British politician, member of the House of Lords since 1981 20 April – Doreen Massey, Baroness Massey of Darwen, 85, British politician, member of the House of Lords (since 1999). 23 April – Frank Field, Baron Field of Birkenhead, 81, British politician, MP (1979–2019) and member of the House of Lords (since 2020). David Marquand, 89, British politician and academic administrator, MP (1966–1977) and principal of Mansfield College, Oxford (1996–2002). 29 April – Andrew Stunell, Baron Stunell, 81, British politician, MP (1997–2015) and member of the House of Lords (since 2015). 10 May – Colin Breed, 76, British politician, MP (1997–2010). (death announced on this date) 12 May – Michael Brudenell-Bruce, 8th Marquess of Ailesbury, 98, British hereditary peer, army officer and stockbroker, member of the House of Lords (1974–1999). 24 May – Stuart Borrowman, 71, Scottish politician. 5 June – Charles Allsopp, 6th Baron Hindlip, 83, British peer and businessman, member of the House of Lords (1993–1999). 26 June – Richard Taylor, 89, British politician, MP (2001–2010). 29 July – Robert Fellowes, Baron Fellowes, 82, British courtier, private secretary to the sovereign (1990–1999) and member of the House of Lords (1999–2022). Peter Reddaway, 84, British-American political scientist. 4 August – Anthony Hamilton-Smith, 3rd Baron Colwyn, 82, British dentist and peer, member of the House of Lords (1967–2022). 22 August – Delwyn Williams, 85, British politician and solicitor, MP (1979–1983).
== Occurrence and production == Polonium is a very rare element in nature because of the short half-lives of all its isotopes. Nine isotopes, from 210 to 218 inclusive, occur in traces as decay products: 210Po, 214Po, and 218Po occur in the decay chain of 238U; 211Po and 215Po occur in the decay chain of 235U; 212Po and 216Po occur in the decay chain of 232Th; and 213Po and 217Po occur in the decay chain of 237Np. (No primordial 237Np survives, but traces of it are continuously regenerated through (n,2n) knockout reactions in natural 238U. The ratio of neptunium to uranium is around 1 to 1012, but having a shorter half-life the ratio in terms of radioactivity is around 1 to 109. 217Po only occurs if 225Ra decays to 221Rn, with a probability of 0.000026, and then the 221Rn decays to 217Po with probability 0.22.) Of these, 210Po is the only isotope with a half-life longer than 3 minutes. Polonium can be found in uranium ores at about 0.1 mg per metric ton (1 part in 1010), which is approximately 0.2% of the abundance of radium. The amounts in the Earth's crust are not harmful. Polonium has been found in tobacco smoke from tobacco leaves grown with phosphate fertilizers. Because it is present in small concentrations, isolation of polonium from natural sources is a tedious process. The largest batch of the element ever extracted, performed in the first half of the 20th century, contained only 40 Ci (1.5 TBq) (9 mg) of polonium-210 and was obtained by processing 37 tonnes of residues from radium production.
However, this occurs mostly in prostate cancer patients who take very high doses of cyproterone acetate; liver toxicity has not been reported in transgender women. Cyproterone acetate also has a variety of other adverse effects, such as fatigue and weight gain, and risks, such as blood clots and benign brain tumors, among others. High dosages of cyproterone-based medication have been linked with meningioma. Periodic monitoring of liver enzymes and prolactin levels may be advisable during cyproterone acetate therapy. Medroxyprogesterone acetate is a progestin that is related to cyproterone acetate and is sometimes used as an alternative to it. It is specifically used as an alternative to cyproterone acetate in the United States, where cyproterone acetate is not approved for medical use and is unavailable. Medroxyprogesterone acetate suppresses testosterone levels in transgender women similarly to cyproterone acetate. Oral medroxyprogesterone acetate has been found to suppress testosterone levels in men by about 30 to 75% across a dosage range of 20 to 100 mg/day. In contrast to cyproterone acetate however, medroxyprogesterone acetate is not also an androgen receptor antagonist. Medroxyprogesterone acetate has similar side effects and risks as cyproterone acetate, but is not associated with liver problems. Numerous other progestogens and by extension antigonadotropins have been used to suppress testosterone levels in men and are likely useful for such purposes in transgender women as well.
Bickley and Sundridge (17,766) Bromley Common and Holwood (18,781) Bromley Town (15,400) Hayes and Coney Hall (15,908) Plaistow (13,478) Shortlands and Park Langley (16,207) The 2021 U.K. census reported the entire borough of Bromley overall had a population 329,991.
This is likely a result of defects in the corticotrophin hormone axis or other abnormalities with neurotransmission. Some patients may also have xanthomas, which are fat deposits that accumulate below the skin. These usually appear waxy and yellow, predominantly around the eyes and joints. This condition results from an accumulation of lipids within the blood. If gallstones prevent bile flowing from the pancreas to the small intestine, it can lead to gallstone pancreatitis. Physical symptoms include nausea, vomiting, and abdominal pain. Bile is required for the absorption of fat-soluble vitamins. As such, patients with cholestasis may present with a deficiency in vitamins A, D, E, or K due to a decline in bile flow. Patients with cholestasis may also experience pale stool and dark urine.
Sources: en.wikipedia.org
Membrane fusion proteins (not to be confused with chimeric or fusion proteins) are proteins that cause fusion of biological membranes. Membrane fusion is critical for many biological processes, especially in eukaryotic development and viral entry. Fusion proteins can originate from genes encoded by infectious enveloped viruses, ancient retroviruses integrated into the host genome, or solely by the host genome. Post-translational modifications (PTM) made to fusion proteins by host enzymes (in particular the addition of sugars through glycosylation or the addition of acetyl groups) can drastically affect their relative ability to fuse membranes, also known as their fusogenicity.
Each lung is enclosed within a pleural sac of two pleurae which allows the inner and outer walls to slide over each other whilst breathing takes place, without much friction. The inner visceral pleura divides each lung as fissures into sections called lobes. The right lung has three lobes and the left has two. The lobes are further divided into bronchopulmonary segments and lobules. The lungs have a unique blood supply, receiving deoxygenated blood sent from the heart to receive oxygen (the pulmonary circulation) and a separate supply of oxygenated blood (the bronchial circulation). The tissue of the lungs can be affected by several respiratory diseases including pneumonia and lung cancer. Chronic diseases such as chronic obstructive pulmonary disease and emphysema can be related to smoking or exposure to harmful substances. Diseases such as bronchitis can also affect the respiratory tract. Medical terms related to the lung often begin with pulmo-, from the Latin pulmonarius (of the lungs) as in pulmonology, or with pneumo- (from Greek πνεύμων "lung") as in pneumonia. In embryonic development, the lungs begin to develop as an outpouching of the foregut, a tube which goes on to form the upper part of the digestive system. When the lungs are formed the fetus is held in the fluid-filled amniotic sac and so they do not function to breathe. Blood is also diverted from the lungs through the ductus arteriosus. At birth however, air begins to pass through the lungs, and the diversionary duct closes so that the lungs can begin to respire.
== Reaction == The actual reaction catalyzed by AGAT is the synthesis of guanidinoacetate from arginine and glycine, with ornithine as a byproduct. The guanidinoacetate produced is then combined with S-Adenosyl-L-methionine, a reaction catalyzed by GAMT, to produce creatine and S-Adenosyl-L-homocysteine. The mechanism by which the AGAT catalyzes this committed step follows a ping-pong mechanism, and involves the transferring of an amidino group to the Cys407 residue on the protein from L-arginine, which leaves as L-ornithine. The His303 residue then extracts a proton from glycine, which then picks up the amidino group from Cys407 in exchange for a proton to become guanidinoacetate and renew the catalyst.
The BSE SENSEX (also known as the S&P Bombay Stock Exchange Sensitive Index or simply SENSEX) is an Indian free-float market-weighted stock market index of 30 well-established and financially sound companies listed on the Bombay Stock Exchange. The 30 constituent companies which are some of the largest and most actively traded stocks, are representative of various industrial sectors of the Indian economy. Published since 1 January 1986, the S&P BSE SENSEX is regarded as the pulse of the domestic stock markets in India. The base value of the SENSEX was taken as 100 on 1 April 1979 and its base year as 1978–79. On 25 July 2001, BSE launched DOLLEX-, a dollar-linked version of the SENSEX.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.